High use of short-acting β2-agonists in COPD is associated with an increased risk of exacerbations and mortality [0.03%]
频繁使用短效β2受体激动剂与慢性阻塞性肺疾病急性加重和死亡风险增加有关
Christer Janson,Fredrik Wiklund,Gunilla Telg et al.
Christer Janson et al.
Background: Short-acting β2-agonist (SABA) overuse has been associated with an increased risk of exacerbations in asthma; however, less is known about SABA use in COPD. Our aim was to describe SABA use and investigate po...
Evaluating the impact of cash transfers on tuberculosis (ExaCT TB): a stepped wedge cluster randomised controlled trial [0.03%]
现金转帐对肺结核影响的评价（ExaCT TB）：分阶段楔形群随机对照试验
Priya B Shete,Jillian L Kadota,Grace Nanyunja et al.
Priya B Shete et al.
Background: Mitigating financial barriers to tuberculosis (TB) diagnosis and treatment is a core priority of the global TB agenda. We evaluated the impact of a cash transfer intervention on completion of TB testing and tr...
Personalising airway clearance in chronic suppurative lung diseases: a scoping review [0.03%]
慢性化脓性肺疾病中个性化支气管清除的范畴回顾性研究
Lynne M Schofield,Sally J Singh,Zarah Yousaf et al.
Lynne M Schofield et al.
Background: Personalised airway clearance techniques are commonly recommended to augment mucus clearance in chronic suppurative lung diseases. It is unclear what current literature tells us about how airway clearance regi...
Validation of the qSOFA and CRB-65 in SARS-CoV-2-infected community-acquired pneumonia [0.03%]
qSOFA和CRB-65在社区获得性肺炎新型冠状病毒肺炎感染者中的验证研究
Tina Richter,Falko Tesch,Jochen Schmitt et al.
Tina Richter et al.
Rationale: Prognostic accuracy of the quick sequential organ failure assessment (qSOFA) and CRB-65 (confusion, respiratory rate, blood pressure and age (≥65 years)) risk scores have not been widely evaluated in patients ...
Exercise responses and mental health symptoms in COVID-19 survivors with dyspnoea [0.03%]
新冠肺炎伴呼吸困难康复患者的运动反应和心理健康症状之间的关系
Kathryn M Milne,Juthaporn Cowan,Michele R Schaeffer et al.
Kathryn M Milne et al.
Objectives: Dyspnoea is a common persistent symptom post-coronavirus disease 2019 (COVID-19) illness. However, the mechanisms underlying dyspnoea in the post-COVID-19 syndrome remain unclear. The aim of our study was to e...
Lung microhaemorrhage drives oxidative/inflammatory damage in α1-antitrypsin deficiency [0.03%]
α1-抗胰蛋白酶缺乏症中的肺微出血驱动氧化/炎症损伤
Cesare Saltini,Naweed Mohammad,Yan Xin et al.
Cesare Saltini et al.
Background: Animal models using intratracheal instillation show that elastase, unopposed by α1-antitrypsin (AAT), causes alveolar damage and haemorrhage associated with emphysematous changes. The aim of the present study...
Impact of high- and low-flow nebulised saline on airway hydration and mucociliary transport [0.03%]
高流速和低流速雾化盐水对气道湿润及黏液纤毛清除的影响
Susyn Kelly,Matthew Valentine,Wei Hang Chua et al.
Susyn Kelly et al.
Background: Nebulised drugs, including osmotic agents and saline, are increasingly used during noninvasive respiratory support, including nasal high-flow therapy. The authors conducted an in vitro study to compare the hyd...
Patient attitudes to nebulised antibiotics in the treatment of bronchiectasis: a mixed-methods study [0.03%]
支气管扩张症患者对吸入性抗生素治疗的态度：一种混合研究方法的研究
John Davison,Anna Robinson-Barella,Gareth Davies et al.
John Davison et al.
Background: Regular daily nebulised antibiotics are widely used in managing bronchiectasis. This patient population typically has severe bronchiectasis requiring multiple other medications. Given that little is known abou...
Computed tomography measure of lung injury and future interstitial features: the CARDIA Lung Study [0.03%]
计算冠状动脉CT测量的肺损伤和未来的间质特征：CARDIA肺研究
Gabrielle Y Liu,Laura A Colangelo,Samuel Y Ash et al.
Gabrielle Y Liu et al.
Introduction: Visually normal areas of the lung with high attenuation on computed tomography (CT) imaging, termed CT lung injury, may represent injured but not yet remodelled lung parenchyma. This prospective cohort study...
The RISE study protocol: resilience impacted by positive stressful events for people with cystic fibrosis [0.03%]
囊性纤维化患者积极应激事件对其复原力影响的RISE研究方案
Els van der Heijden,Rutger M van den Bor,Cornelis K van der Ent et al.
Els van der Heijden et al.
Introduction: For people with cystic fibrosis (CF), gaining access to elexacaftor/tezacaftor/ivacaftor (ETI) therapy, a new modulator drug combination, is perceived as a positive life event. ETI leads to a strong improvem...